Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.32 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.32 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL803306 | 0.94 | — | — | |
| 2-Methoxyethanol SCHEMBL31177228 | 0.92 | HPGD (0.33) | ADORA3ADORA2AADORA2B | |
| SCHEMBL12743131 | 0.91 | ADORA3 (0.33) | ADORA3ADORA2AADORA2B | |
| SCHEMBL15503042 | 0.90 | ALOX12 (0.31) | ADORA3ADORA2AADORA2B | |
| SCHEMBL24621700 | 0.89 | ADORA3 (0.33) | ADORA3ADORA2AADORA2B | |
| SCHEMBL17167184 | 0.89 | ADORA3 (0.33) | ADORA3ADORA2AADORA2B | |
| SCHEMBL2568708 | 0.87 | ADORA3 (0.37) | ADORA3ADORA2AADORA2B | |
| SCHEMBL16303082 | 0.86 | ADORA3 (0.32) | ADORA3ADORA2AADORA2B | |
| SCHEMBL29713990 | 0.85 | PSMB8 (0.31) | — | |
| SCHEMBL3521348 | 0.84 | TSHR (0.34) | TSHRMAPK1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115919755-A | Low-concentration hydrogel and preparation method and application thereof | 沈阳药科大学 | 2023-04-07 | — | — | CN | claimed |
| CN-115819550-A | Interleukin-2 mutant and polyethylene glycol modifier and preparation method thereof | 江苏众红生物工程创药研究院有限公司 | 2023-03-21 | — | — | CN | claimed |
| CN-110251731-B | Islet cell microcapsule for tissue engineering and preparation method thereof | 山东百多安医疗器械股份有限公司 | 2021-09-03 | — | — | CN | claimed |
| CN-110201234-B | Prostate cell microcapsule for tissue engineering and preparation method thereof | 山东百多安医疗器械股份有限公司 | 2021-09-03 | — | — | CN | claimed |
| CN-104693433-B | A kind of Pegylation Amifostine, preparation method and its usage | 国家纳米科学中心 | 2017-06-06 | — | — | CN | claimed |
| CN-118344617-A | Bioactive hydrogel and preparation method and application thereof | 香港中文大学 | 2024-07-16 | — | — | CN | disclosed |
| CN-117731826-A | Platelet-rich plasma hydrogel with growth factors slowly released and preparation method and application thereof | 武汉理工大学 | 2024-03-22 | — | — | CN | disclosed |
| CN-115919755-A | Low-concentration hydrogel and preparation method and application thereof | 沈阳药科大学 | 2023-04-07 | — | — | CN | disclosed |
| CN-115869456-A | Preparation of in-situ gelation anti-swelling enhanced tissue adhesive material | 上海其胜生物制剂有限公司 | 2023-03-31 | — | — | CN | disclosed |
| CN-115819550-A | Interleukin-2 mutant and polyethylene glycol modifier and preparation method thereof | 江苏众红生物工程创药研究院有限公司 | 2023-03-21 | — | — | CN | disclosed |
| CN-114306722-B | Injectable hydrogel type biological adhesive and preparation and application thereof | 华东理工大学 | 2022-12-30 | — | — | CN | disclosed |
| CN-114306722-A | Injectable hydrogel type biological adhesive and preparation and application thereof | 华东理工大学 | 2022-04-12 | — | — | CN | disclosed |
| US-20140044672-A1 | CONJUGATES OF A GM-CSF MOIETY AND A POLYMER | NEKTAR THERAPEUTICS (US) | 2014-02-13 | — | — | US | disclosed |
| US-8470891-B2 | Biodegradable block polymers for drug delivery, and methods related thereto | INTERNATIONAL BUSINESS MACHINES CORPORATION (US) | 2013-06-25 | — | — | US | disclosed |
| US-8470891-B2 | Biodegradable block polymers for drug delivery, and methods related thereto | INTERNATIONAL BUSINESS MACHINES CORPORATION (US) | 2013-06-25 | — | — | US | disclosed |
| US-20120322737-A1 | MODIFIED RECOMBINANT FACTOR VIII AND VON WILLEBRAND FACTOR AND METHODS OF USE | BAXTER HEALTHCARE S.A. (CH) | 2012-12-20 | — | — | US | disclosed |
| US-20120083767-A1 | IMPLANTABLE BIOREACTOR FOR DELIVERY OF PARACRINE FACTORS | THE JOHNS HOPKINS UNIVERSITY (US) | 2012-04-05 | — | — | US | disclosed |
| US-20110152167-A1 | BIODEGRADABLE BLOCK POLYMERS FOR DRUG DELIVERY, AND METHODS RELATED THERETO | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2011-06-23 | — | — | US | disclosed |
| US-20110152167-A1 | BIODEGRADABLE BLOCK POLYMERS FOR DRUG DELIVERY, AND METHODS RELATED THERETO | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2011-06-23 | — | — | US | disclosed |
| WO-2010117460-A1 | SURFACE MODIFICATION OF REVERSE OSMOSIS MEMBRANES BY HYDROPHILIC DENDRITIC POLYMERS | MICHIGAN MOLECULAR INSTITUTE (US) | 2010-10-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120322737-A1 | MODIFIED RECOMBINANT FACTOR VIII AND VON WILLEBRAND FACTOR AND METHODS OF USE | F8, F5, F13B | ADORA3 2154/4885ADORA2A 1684/4885ADORA2B 1180/4885 |
| US-20140044672-A1 | CONJUGATES OF A GM-CSF MOIETY AND A POLYMER | CSF3R, GMFG, CSF1R | ADORA3 4241/4885ADORA2A 4299/4885ADORA2B 4596/4885 |
| US-20110152167-A1 | BIODEGRADABLE BLOCK POLYMERS FOR DRUG DELIVERY, AND METHODS RELATED THERETO | SAMM50, ADRM1, UFM1 | ADORA3 2115/4885ADORA2A 2587/4885ADORA2B 831/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.